Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Unified Patent Court
A distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF.   5 September 2024
Americas
If adopted, the pending rule would reshape litigation strategy and offer patent defendants a valuable tool, say Kristen Lovin and Niall Frizzell of Keker, Van Nest & Peters   29 August 2024
Europe
How much evidence is usually required to establish a prejudice at the European Patent Office, and what are the potential pitfalls in this line of argument? Stuart McKellar of EIP explores   20 August 2024
Americas
Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones.   1 August 2024
Biotechnology
AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.   25 July 2024
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.   27 June 2024
Americas
Brazil’s updated regulations for its flagship partnerships programme marks a renewed effort to strengthen the nation's health sector, says Rob Rodrigues of RNA Law.   25 June 2024
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.   20 June 2024
Europe
Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.   18 June 2024
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.   16 May 2024